uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: GlobeNewswire
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AMT-130, the Company’s gene therapy candidate for the treatment of Huntington’s disease. AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients. AMT-130 also is unique in that it targets the highly toxic exon1 protein fragment that is even more toxic than the mutant huntingtin protein. “Achieving Fast Track Designation from the FDA underscores the high unmet medical need for patients suffering from Huntington’s disease, for which there are currently no approved, disease-modifying treatments,” stated Matt Kapusta, chief executive off
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- uniQure (NASDAQ: QURE) had its price target lowered by analysts at Mizuho from $10.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
- uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- uniQure (NASDAQ: QURE) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- uniQure (NASDAQ: QURE) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "buy" rating to a "neutral" rating. They now have a $8.00 price target on the stock.MarketBeat
- uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressGlobeNewswire
QURE
Earnings
- 11/7/23 - Miss
QURE
Sec Filings
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- 4/12/24 - Form PRE
- QURE's page on the SEC website